215 related articles for article (PubMed ID: 16008344)
1. Inactivation of endotoxin by human plasma gelsolin.
Bucki R; Georges PC; Espinassous Q; Funaki M; Pastore JJ; Chaby R; Janmey PA
Biochemistry; 2005 Jul; 44(28):9590-7. PubMed ID: 16008344
[TBL] [Abstract][Full Text] [Related]
2. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components.
Bucki R; Byfield FJ; Kulakowska A; McCormick ME; Drozdowski W; Namiot Z; Hartung T; Janmey PA
J Immunol; 2008 Oct; 181(7):4936-44. PubMed ID: 18802097
[TBL] [Abstract][Full Text] [Related]
3. Identification of single amino acid residues essential for the binding of lipopolysaccharide (LPS) to LPS binding protein (LBP) residues 86-99 by using an Ala-scanning library.
Reyes O; Vallespi MG; Garay HE; Cruz LJ; González LJ; Chinea G; Buurman W; Araña MJ
J Pept Sci; 2002 Apr; 8(4):144-50. PubMed ID: 11991204
[TBL] [Abstract][Full Text] [Related]
4. A synthetic lipopolysaccharide-binding peptide based on amino acids 27-39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood.
de Haas CJ; van der Tol ME; Van Kessel KP; Verhoef J; Van Strijp JA
J Immunol; 1998 Oct; 161(7):3607-15. PubMed ID: 9759883
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of truncated human lipopolysaccharide-binding protein in Escherichia coli.
Kohara J; Tsuneyoshi N; Gauchat JF; Kimoto M; Fukudome K
Protein Expr Purif; 2006 Oct; 49(2):276-83. PubMed ID: 16839777
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor C competes against LBP to bind lipopolysaccharide and neutralizes the endotoxicity.
Li P; Ho B; Ding JL
J Endotoxin Res; 2007; 13(3):150-7. PubMed ID: 17621557
[TBL] [Abstract][Full Text] [Related]
7. Structure of a synthetic fragment of the lipopolysaccharide (LPS) binding protein when bound to LPS and design of a peptidic LPS inhibitor.
Pristovsek P; Simcic S; Wraber B; Urleb U
J Med Chem; 2005 Dec; 48(24):7911-4. PubMed ID: 16302828
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lipopolysaccharide-binding functions of CD14 and MD-2.
Koraha J; Tsuneyoshi N; Kimoto M; Gauchat JF; Nakatake H; Fukudome K
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1292-7. PubMed ID: 16275943
[TBL] [Abstract][Full Text] [Related]
9. Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS-induced NF-kappaB activation.
Hamann L; Schumann RR; Flad HD; Brade L; Rietschel ET; Ulmer AJ
Eur J Immunol; 2000 Jan; 30(1):211-6. PubMed ID: 10602043
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of LPS-responses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interaction.
Araña Mde J; Vallespi MG; Chinea G; Vallespi GV; Rodriguez-Alonso I; Garay HE; Buurman WA; Reyes O
J Endotoxin Res; 2003; 9(5):281-91. PubMed ID: 14577844
[TBL] [Abstract][Full Text] [Related]
11. Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics.
Zorko M; Jerala R
J Antimicrob Chemother; 2008 Oct; 62(4):730-7. PubMed ID: 18635521
[TBL] [Abstract][Full Text] [Related]
12. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.
Lamping N; Dettmer R; Schröder NW; Pfeil D; Hallatschek W; Burger R; Schumann RR
J Clin Invest; 1998 May; 101(10):2065-71. PubMed ID: 9593762
[TBL] [Abstract][Full Text] [Related]
13. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo.
Jiang Z; Hong Z; Guo W; Xiaoyun G; Gengfa L; Yongning L; Guangxia X
Int Immunopharmacol; 2004 Apr; 4(4):527-37. PubMed ID: 15099530
[TBL] [Abstract][Full Text] [Related]
14. Screening of mimetic peptides for CD14 binding site with LBP and antiendotoxin activity of mimetic peptide in vivo and in vitro.
Xu Z; Qian GS; Li Q; Feng QJ; Wu GM; Li KL
Inflamm Res; 2009 Jan; 58(1):45-53. PubMed ID: 19115038
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of murine and human recombinant LPS-binding protein (LBP) within LPS and gram negative bacteria.
Lengacher S; Jongeneel CV; Le Roy D; Lee JD; Kravchenko V; Ulevitch RJ; Glauser MP; Heumann D
J Inflamm; 1995-1996; 47(4):165-72. PubMed ID: 9144073
[TBL] [Abstract][Full Text] [Related]
16. High-throughput characterization of lipopolysaccharide-binding proteins using mass spectrometry.
Kim YG; Yang YH; Kim BG
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(31):3323-6. PubMed ID: 21035409
[TBL] [Abstract][Full Text] [Related]
17. Low potency of Chlamydophila LPS to activate human mononuclear cells due to its reduced affinities for CD14 and LPS-binding protein.
Tsutsumi-Ishii Y; Shimada K; Daida H; Toman R; Nagaoka I
Int Immunol; 2008 Feb; 20(2):199-208. PubMed ID: 18056918
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of lipid A-mediated type I interferon induction by bactericidal/permeability-increasing protein (BPI).
Azuma M; Matsuo A; Fujimoto Y; Fukase K; Hazeki K; Hazeki O; Matsumoto M; Seya T
Biochem Biophys Res Commun; 2007 Mar; 354(2):574-8. PubMed ID: 17239348
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effects of sCD14 and LBP on LPS-host cell interactions.
Kitchens RL; Thompson PA
J Endotoxin Res; 2005; 11(4):225-9. PubMed ID: 16176659
[TBL] [Abstract][Full Text] [Related]
20. The BPI/LBP family of proteins: a structural analysis of conserved regions.
Beamer LJ; Carroll SF; Eisenberg D
Protein Sci; 1998 Apr; 7(4):906-14. PubMed ID: 9568897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
